SEC Comment Letter for NEKTAR THERAPEUTICS (NKTR) (CIK 0000906709) (NKTR) — Jan 16, 2018

NEKTAR THERAPEUTICS (NKTR) (CIK 0000906709)
Date: Jan. 16, 2018 · CIK: 0000906709 · Accession: 0000000000-18-001455

View on Edgar

AI Filing Summary & Sentiment

Date

January 16, 2018

Author

Not clearly detected

Form

UPLOAD

Company

NEKTAR THERAPEUTICS (NKTR) (CIK 0000906709)

Letter

January 16, 2018 Gil M. Labrucherie Senior Vice President and Chief Financial Officer Nektar Therapeutics 455 Mission Bay Boulevard South San Francisco, California 94158 Nektar Therapeutics Form 10-K for the Fiscal Year Ended December 31, 2016 Filed March 1, 2017 File No. 000-24006Re: Dear Mr. Labrucherie: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence by the staff. Division of Corporation Finance Office of Healthcare & Insurance

Show Raw Text

January 16, 2018
Gil M. Labrucherie
Senior Vice President and Chief Financial Officer
Nektar Therapeutics
455 Mission Bay Boulevard South
San Francisco, California 94158
Nektar Therapeutics
Form 10-K for the Fiscal Year Ended December 31, 2016
Filed March 1, 2017
File No. 000-24006Re:
Dear Mr. Labrucherie:
            We have completed our review of your filings.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence by the staff.
Division of Corporation Finance
Office of Healthcare & Insurance

SecProbe.io